

AUTHOR INDEX

- Aggio S, *see* Longhini, 199
Aldus U, *see* Linz, 873
Alimenti M, *see* Carosella, 417
Anand I, *see* Ferrari, 979
Anand IS, *see* Vali, 761
Andersen MF, *see* Sorensen, 203
Ansani L, *see* Longhini, 199
Antonaccio MJ, Gomoll AW, Byrne JE. Encainide, 691
Arakawa K. Non-pharmacological measures for lowering blood pressure, 847
Arcara G, *see* Arosio, 835
Arosio E, Pancera P, Arcara G, Priante F, Montesi G, Zannoni M, Lechi A. Effects of long-term nicardipine treatment on hemodynamics of large arteries in essential hypertension, 835
Baker SG, *see* Berger, 219
Baracca E, *see* Longhini, 199
Barba G, *see* Galletti, 135
Barnabei R, *see* Pahor, 163
Bauer R, Busch U, Lutinsky L, van de Flied E, Langhammer HR, Pabst HW. The efficacy of nifedipine and acebutolol in coronary artery disease assessed by radionuclide ventriculography, 287
Beavers DG, *see* Perry, 815
Behr U, *see* Franz, 313
Berenger FP, *see* Friggi, 445
Berger GMB, Marais AD, Seftel HC, Baker SG, Mendelsohn D, Welsh NH, Joffe BI. Treatment of hypercholesterolemia with the HMG Co A reductase inhibitor, simvastatin, 219
Berkboom G, *see* Unger, 459
Bernini GP, Lucarini AR, Vivaldi MS, Del Corso C, Lenzi M, Salvetti A. Nalozone does not antagonize the antihypertensive effects of chronic captopril therapy in hypertensive patients, 829
Bertuch H, *see* Stark, 183
Bestetti RB, Soares EG, Sales-Neto VN, Oliveira JSM. The ajmaline test as a method to disclose latent experimental Chagas' heart disease, 171
Betteridge DJ, *see* Feher, 333
Bianchini C, *see* Gennari, 319
Billaud EB, *see* Lacolley, 859
Binetti G, Rubino I, Varani E, Spadoni R, Ferretti RM, Cervi V, Magnani B. Felodipine in severe chronic congestive heart failure: Acute effects on central hemodynamics and regional blood flow distribution, 903
Binetti G, *see* Galiè, 91
Bodard H, *see* Friggi, 445
Branzi A, *see* Galiè, 91
Brilla CG, Krämer B, Hoffmeister HM, Müller-Schauenburg, Rislér T, Seipel L. Low-dose enalapril in severe chronic heart failure, 211
Bristow MR, Port JD, Gilbert EM. Role of receptor regulation in treatment of heart failure, 971
Buracchi P, *see* Gennari, 319
Burgess RA, *see* Dodd, 545
Busch U, *see* Bauer, 287
Byrne JE, *see* Antonaccio, 691
Camilleri, JP. Sarcolemmal changes in reperfusion injury, 893
Cappuccio, P, *see* Galletti, 135
Carbonin PU, *see* Carosella, 417
Carbonin PU, *see* Pahor, 163
Carosella L, Menichelli P, Alimenti M, Zuccala G, Gemma A, Cocchi A, Carbonin PU. Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses, 417
Carpentier RG, *see* Salvatici, 177
Carter AJ, *see* Dodd, 545
Carvalho JS, *see* Redington, 21
Carryl OR, *see* Salvatici, 177
Ceconi C, *see* Ferrari, 403
Cerenka J, *see* Sullivan, 57
Cervi V, *see* Binetti, 903
Challenor VF, Waller DG, George CF. Beta-adrenoceptor antagonists plus nifedipine in the treatment of chronic stable angina pectoris, 275
Chance B, *see* Wilson, 995
Cheng, C-C, *see* Lee, 529
Cheng, M-F, *see* Lee, 529
Cheng, W-J, *see* Lee, 529
Chesboro JH, Opie LH, Fuster V. The recent trials for aspirin in the prevention of cardiovascular mortality, 353
Clement DL, *see* Jordaens, 155
Coats AJS, Conway J, Somers VK, Isea JE, Sleight P. Ambulatory pressure monitoring in the assessment of antihypertensive therapy, 303
Cocchi A, *see* Carosella, 417
Cohn JN. An explanation for varying views about digitalis efficacy in congestive heart failure, 19
Colardyn F, *see* Jordaens, 155
Connell MJ, *see* Silver, 675
Conroy RC, *see* McDonald, 913
Conway J, *see* Coats, 303
Cowley AJ, Hampton JR. Peripheral effect of ACE inhibitors and other vasodilators, 1017
Cumiskey WR, *see* Silver, 675
Dählöf C, Dimenäs E, Olofsson B. Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy, 919
Dallocchio M, *see* Gosse, 525
Danne, O, *see* Eichstaedt, 779
Davies, MJ. The pathological basis of angina pectoris, 249
Deby, C. The role of oxygen metabolism in ischemia-reperfusion, 893
De Champlain J, *see* Rouleau, 883
Degre S, *see* Ibrahim, 557
Del Corso C, *see* Bernini, 829
Depelchin P, *see* Ibrahim, 557
Di Gennaro M, *see* Pahor, 163
Dillon KM, *see* Silver, 675
Dimenäs E, *see* Dahlöf, 919
Dineen M, *see* Sullivan, 57
Distante A, Morales M-A, Piacenti M, Sabino F, L'Abbate A. An acute non-invasive study aimed to assess the inotropic effect of oral ibopamine in patients with mild congestive heart failure, 1025
Dodd MG, Gardiner DG, Carter AJ, Sutton MR, Burgess, RA. The hemodynamic properties of amlodipine in anesthetized and conscious dogs: Comparison with nitrendipine and influence of beta-adrenergic blockade, 545
Dolva LO, *see* Gullestad, 63
Dougherty FC, *see* Eichstaedt, 779
Doussau M-P, *see* Richer, 865
Duncan W, *see* McMahon, 753
Eichstaedt HW, Felix R, Danne O, Dougherty FC, Schmutzler H. Imaging of acute myocardial infarction by magnetic resonance tomography (MRT) using the paramagnetic relaxation substance gadolinium-DTPA, 779
Esclapez F, *see* Friggi, 445
Ezrin AM, *see* Silver, 675
Faergeman O, *see* Sorensen, 203
Farber NE, *see* Gross, 535
Farsang C, *see* Kiss, 413
Fauler J, Frölich JC. Cardiovascular effects of leukotrienes, 499
Feher MD, Betteridge DJ, Lipids, lipoproteins, and coronary heart disease: Implications for antihypertensive therapy, 333
Feld GK, Nademanee K, Noll E, Singh BN. Oral N-acetylprocainamide compared to quinidine plus digoxin in the chronic suppression of atrial flutter in humans, 191
Felix R, *see* Eichstaedt, 779
Ferrari R, Anand I. Neurohumoral changes in untreated heart failure, 979
Ferrari R, Raddino R, Ceconi C. Prolonged protective effect of the calcium-antagonist anipamil on the ischemic reperfused rabbit myocardium: Comparison with verapamil, 403
Ferretti RM, *see* Binetti, 903
Fontaine J, *see* Unger, 459
Franz I-W, Tönnemann U, Behr U, Ketelhut R. Regression of left ventricular hypertrophy by acebutolol and nifedipine, 313
Friberg M, *see* Poulsen, 141
Friedman HS, *see* Shah, 929
Friggi A, Bodard H, Berenger FP, Esclapez F, Roland PH. Effects of SIN-1 on peripheral hemodynamics and viscoelastic properties of aorta in anesthetized rabbits, 445
Frolich ED. Life's quality: A major consideration in health care delivery—Especially with hypertensive diseases, 821
Frolich ED, *see* Natsume, 433
Frölich JC, *see* Fauler, 499
Fudo T, Kambura, Kawai C. Myocardial blood flow and metabolism in coronary artery patients with or without congestive heart failure, 1001
Fuster V, *see* Chesboro, 353
Fuster V, *see* Stein, 797
Futishausen WJ. The costs of treatment of hypertension in Switzerland and worldwide, 931
Gagliardi R, *see* Galletti, 135
Galiè N, Metalli M, Zannoni R, Binetti G, Branzi A, Magnani B. Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs, 91

- Galletti F, Strazzullo P, Cappuccio FP, Barba G, Giorgione N, Gagliardi R, Mancini M. Calcium-channel blockers and sodium intake: A controlled study in patients with essential hypertension, 135
- Gardiner DG, *see* Dodd, 545
- Geiger M, *see* Kunze, 73
- Gemma A, *see* Carosella, 417
- Gennari C, Nami R, Pavese G, Gragnani S, Bianchini C, Buracchi P. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension, 319
- George CF, *see* Challenor, 275
- Geraud, G. Reperfusion of the ischemic brain, 894
- Ghirardi P, *see* Longhini, 199
- Gilbert EM, *see* Bristow, 971
- Giorgione N, *see* Galletti, 135
- Giudicelli, J-F, *see* Richer, 865
- Goldstein S, *see* Pitt, 7
- Gomoll AW, *see* Antonaccio, 691
- Gosse P, Lacroix P, Roudaut R, Dallochio M. Left ventricular mass changes with nicardipine therapy in essential hypertension, 525
- Gotanda K, Yokoyama H, Satoh K, Taira N. Cardiohemodynamic effects of cromakalim and pinacidil, potassium-channel openers, in the dog, with special reference to venous return, 507
- Gragnani S, *see* Gennari, 319
- Gross GJ, Farber NE, Pieper GM. Effect of amlodipine on myocardial functional and metabolic recovery following coronary occlusion and reperfusion in dogs, 535
- Gullestad L, Dolva LO, Kjeldsen SE, Eide I, Kjekshus J. Effects of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise, 63
- Guth BD, *see* Schulz, 43
- Halabi A, Linde M, Zeidler H, König J, Kirch W. Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives, 441
- Hampton JR. Treating mild hypertension—An unnecessary luxury, 749
- Hampton JR, *see* Cowley, 1017
- Harrington LT, *see* Ritchie, 341
- Hanssen M, *see* Monassier, 896
- Harris P. Congestive cardiac failure: The syndrome of volume expansion, 941
- Hashimoto K, Watanabe K, Mitsuhashi H. Antiarrhythmic effect of a new Class I antiarrhythmic drug, AN-132, on ventricular arrhythmias in beagles, 683
- Heagerty AM, *see* Maclean, 343
- Henderson AH. Syndrome X, 271
- Henderson AH. Treatment of choice in early congestive heart failure—Considerations for the future, 1007
- Henderson AH. Vascular endothelium in ischemic heart disease: Possible role for endothelium-derived relaxing factor, 241
- Heusch G, *see* Schulz, 43
- Himanen P, *see* Sykulski, 427
- Hoffmeister HM, *see* Brilla, 211
- Holt DW, *see* Robinson, 25
- Hönlgl K, *see* Stark, 183
- Ibrahim TM, Unger P, Sobolski J, Depelchin P, Jottrand M, Degre S. Hemodynamic effects of SIN-1 in acute left heart failure, 557
- Imagawa J, Satoh K, Taira N. Coronary vasodilator and cardiac effects of NKY-722, a novel hydrophilic 1,4-dihydropyridine derivative, in the blood-perfused dog heart, 81
- Isaacson RL, *see* Salvatici, 177
- Isea JE, *see* Coats, 303
- Joffe BI, *see* Berger, 219
- Johnson A, *see* McMahon, 753
- Johnston A, *see* Robinson, 25
- Jonasson T, *see* Leppert, 397
- Jordaens LJ, Colardyn F, Clement DL. A comparison of sotalol and procainamide in symptomatic ventricular tachycardia, 155
- Jottrand M, *see* Ibrahim, 557
- Juneau C, *see* Rouleau, 883
- Kaiser J, *see* Linz, 873
- Kambara H, *see* Fudo, 1001
- Kardon MR, *see* Natsume, 433
- Kawai C, *see* Fudo, 1001
- Keller N, *see* Sykulski, 427
- Ketelhut R, *see* Franz, 313
- Kirch W, *see* Halabi, 441
- Kiss I, Farsang C. Nifedipine-prazosin interaction in patients with essential hypertension, 413
- Kjekshus J, *see* Gullestad, 63
- Kjeldsen SE, *see* Gullestad, 63
- Klinkefus, BA, *see* Weishaar, 29
- Kobylarz-Singer, D, *see* Weishaar, 29
- König J, *see* Halabi, 441
- Kornicki P, *see* Mitrovic, 771
- Krämer B, *see* Brilla, 211
- Kramer W, *see* Thormann, 145
- Kremer P, *see* Thormann, 145
- Krusell L, *see* Poulsen, 141
- Kuck K-H, *see* Kunze, 73
- Kunze KP, Schlüter M, Geiger M, Kuck K-H. Diprafenone for treatment of Wolff-Parkinson-White syndrome, 73
- L'Abbate A, *see* Distant, 1025
- Lacolley PJ, Laurent S, Billaud EB, Safar ME. Carotid arterial hemodynamics in hypertension: Acute administration of captopril or cadralazine, 859
- Lacroix P, *see* Gosse, 525
- Langhammer HR, *see* Bauer, 287
- Laurent S, *see* Lacolley, 859
- Lechi A, *see* Arosio, 835
- Lee Y-T, Liao C-S, Wong, ECK, Chen W-J, Chen M-F, Chen, C-C. Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol in healthy Chinese subjects, 529
- Lenzi M, *see* Bernini, 829
- Leppert J, Jonasson T, Nilsson H. The effect of isradipine, a new calcium channel antagonist, in patients with primary Raynaud's phenomenon: A single-blind dose-response study, 397
- Lessem JN, Singh BN. Calcium channel antagonism and beta blockade in combination—A therapeutic alternative in cardiovascular disorders. A review, 355
- Liao C-S, *see* Lee, 529
- Linde M, *see* Halabi, 441
- Linz W, Schölkens BA, Kaiser J, Qi B-Y, Albus U, Petry P. Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipiril, 873
- Lo Giudice P, *see* Pahor, 163
- Longhini C, Ansani L, Musacci GF, Aggio S, Baracca E, Toselli T, Ghirardi P. Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study, 199
- Lopez-Sendon J. Hemodynamic effects of ibopamine in congestive heart failure, 1029
- Louis WJ. The cost of new drugs in the treatment of hypertension—The Australian experience, 825
- Lucarini AR, *see* Bernini, 829
- Lund-Johansen P, *see* Omvik, 517
- Lutlisky L, *see* Bauer, 287
- MacGregor AR, *see* Ritchie, 341
- MacGregor GA. Nifedipine and hypertension: Roles of vasodilation and sodium balance, 295
- Maclean D, Heagerty AM. Nifedipine and/or atenolol for mild to moderate hypertension: A general practice study, 343
- Mancini DM, *see* Wilson, 995
- Mancini M, *see* Galletti, 135
- Magnani B, *see* Galiè, 91
- Magnani B, *see* Binetti, 903
- Man in t' Veld AJ. Is there a place for ibopamine in the treatment of congestive heart failure? 1065
- Marais AD, *see* Berger, 219
- Marcus FI. The use of digitalis for the treatment of congestive heart failure: A tale of its decline and resurrection, 473
- Massingham R, Van Zwieten PA. Bepridil: A pharmacological re-appraisal of its potential beneficial effects in angina and tissue protection following ischemia, 731
- Maurer BJ, *see* McDonald, 913
- McDonald KM, O'Sullivan JJ, McWilliams EW, Conroy RC, Maurer BJ. Acute and long term hemodynamic response to low dose enoximone in refractory heart failure, 913
- McKenna WJ, *see* Robinson, 25
- McMahon FG, Johnson A, Duncan W. Some socioeconomic factors in the selection of blood pressure drugs in New Orleans, Louisiana, 753
- McWilliams EW, *see* McDonald, 913
- Menasché, P. Reperfusion injury: Current concepts and therapeutic implications, 895
- Mendelsohn D, *see* Berger, 219
- Menichelli P, *see* Carosella, 417
- Metalli M, *see* Galiè, 91
- Mitrovic V, Thormann J, Kornicki P, Volz M, Neuss H, Schlepper M. The vasopressor system in patients with heart failure due to idiopathic dilated cardiomyopathy, 771
- Mitsuhashi H, *see* Hashimoto, 683
- Monassier JP, Hanssen M. Myocardial reperfusion in the setting of myocardial infarction: Determinants of cellular salvage, 896
- Montesi G, *see* Arosio, 835
- Morales M-A, *see* Distant, 1025
- Morgan JP, Morgan KG. Intracellular calcium and cardiovascular function in heart failure: Effects of pharmacologic agents, 959
- Morgan KG, *see* Morgan, 959

- Moser M. The costs of treating hypertension, 743
- Müller-Schauenburg W, *see* Brilla, 211
- Mulrow JP, *see* Robinson, 25
- Musacci GF, *see* Longhini, 199
- Myhre T, *see* Sykulski, 427
- Nadamanee K, *see* Feld, 191
- Nadeau, R. Noradrenaline release and myocardial reperfusion, 894
- Nami R, *see* Gennari, 319
- Natsume T, Kardon MR, Pegram BL, Frohlich ED. Ventricular performance in spontaneously hypertensive rats (SHR) with reduced cardiac mass, 433
- Nawroth PP, Stern DM. Interaction of vitamin K-dependent coagulation factors and the endothelium, 117
- Neuss H, *see* Mitrovic, 771
- Nilsson H, *see* Leppert, 397
- Noer I, *see* Poulsen, 141
- Noll E, *see* Feld, 191
- O'Connor DT, *see* Sullivan, 57
- Oliveira JSM, *see* Bestetti, 171
- Olofsson B, *see* Dahlöf, 919
- Omvik P, Lund-Johansen P. Acute and long-term effects of tiapamil at rest and during exercise in essential hypertension, 517
- Opie LH. Beta-blockade and calcium antagonism in practice: Monotherapy or combination? 239
- Opie LH. Calcium channel antagonists: A review, part I: Fundamental properties: Mechanisms, classification, sites of action, 477
- Opie LH. Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials, 478
- Opie LH. Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications, 479
- Opie LH. Calcium channel-antagonists. Part IV: Side-effects and contraindications. Drug interactions and combinations, 480
- Opie LH. Calcium channel antagonists. Part V: Second generation agents, 481
- Opie LH. Calcium channel antagonists. Part VI: Clinical pharmacokinetics of first and second-generation agents, 482
- Opie LH. Digoxin revived? 11
- Opie LH. Pharmacological profile of ibopamine and related dopamine-like agents, 1041
- Opie LH. Pharmacology of acute effort angina, 257
- Opie LH. Reperfusion injury and its mechanism, 894
- Opie LH, *see* Chesebrough, 353
- O'Sullivan JJ, *see* McDonald, 913
- Pabst HW, *see* Bauer, 287
- Packer MH. Why patients with heart failure fail to respond to treatment with vasodilator and inotropic drugs, 1055
- Pacifici L, *see* Pahor, 163
- Pahor M, Lo Giudice P, Bernabei R, Di Gennaro M, Pacifici L, Ramacci MT, Carboni PU. Age-related increase in the incidence of ventricular arrhythmias in isolated hearts from spontaneously hypertensive rats, 163
- Pancera P, *see* Arosio, 835
- Pavese G, *see* Gennari, 319
- Pearson PJ, *see* Vanhoutte, 895
- Pedersen OL, *see* Poulsen, 141
- Pegram BL, *see* Natsume, 433
- Pereda T, *see* Román, 767
- Perry JJ, Beevers DG. ACE inhibitors compared with thiazide diuretics as first-step antihypertensive therapy, 815
- Petry P, *see* Linz, 873
- Pfeiffer MA, *see* Smith, 11
- Piacenti M, *see* Distant, 1025
- Pieper GM, *see* Gross, 535
- Pilger E, *see* Stark, 183
- Pino ME, *see* Román, 767
- Pitt B, Goldstein S. The Captopril-Digoxin Multicenter Research Group study on the comparative steps of captopril and digoxin in patients with mild-moderate heart failure: Implications for therapy, 7
- Port JD, *see* Bristow, 971
- Poulsen L, Friberg M, Noer I, Krusell L, Pedersen OL. Comparison of indapamide and hydrochlorothiazide plus amiloride as a third drug in the treatment of arterial hypertension, 141
- Priante F, *see* Arosio, 835
- Qi, B-Y, *see* Linz, 873
- Quitau K, *see* Sykulski, 427
- Raddino R, *see* Ferrari, 403
- Ramacci MT, *see* Pahor, 163
- Redington AN, Carvalho JS, Shinebourne EA. Does digoxin have a place in the treatment of the child with congenital heart failure, 21
- Remme WJ. Neuroendocrine activation in ischemic cardiomyopathy without failure and in acute myocardial ischemia, 987
- Remme WJ. Vasodilator therapy without converting enzyme inhibition in congestive heart failure—Usefulness and limitations, 375
- Richer C, Doussau M-P, Giudicelli J-F. Differential systemic and regional hemodynamic profiles of four angiotensin-I converting-enzyme inhibitors in the rat, 865
- Risler T, *see* Brilla, 211
- Ritchie LD, Harrington LT, MacGregor AR, Vandenburg MJ. Nifedipine as low-dose monotherapy for essential hypertension: A primary care study, 341
- Robertson JIS. Should the costs of development inhibit research into new antihypertensive drugs? 757
- Robinson K, Johnston A, Walker S, Mulrow JP, McKenna WJ, Holt DW. The digoxin-amiodarone interaction, 25
- Rodighiero V. Effects of cardiovascular disease on pharmacokinetics, 711
- Rolland PH, *see* Friggi, 445
- Román O, Pino ME, Pereda T, Valenzuela A. Effects of pindolol and propranolol on blood lipids in hypertensive patients, 767
- Roudaut R, *see* Gosse, 525
- Rouleau JL, Juneau C, de Champlain J. The use of angiotensin converting enzyme inhibitors in congestive heart failure, 883
- Rubino I, *see* Binetti, 903
- Sabino F, *see* Distant, 1025
- Safar M. Treatment of hypertension based on both systolic and diastolic pressure could influence the cost of therapy, 841
- Safar ME, *see* Lacolley, 859
- Sales-Neto VN, *see* Bestetti, 171
- Salvatici PP, Carryl OR, Isaacson RL, Carpentier RG. Actions and interactions of dihydropyridines and ethanol on the rat sinus node, 177
- Salvetti A, *see* Bernini, 829
- Sato K, *see* Gotanda, 507
- Sato K, *see* Imagawa, 81
- Schlepper M, *see* Mitrovic, 771
- Schlepper M, *see* Thormann, 145
- Schölkens BA, *see* Linz, 873
- Schlüter M, *see* Kunze, 73
- Schmutzler H, *see* Eichstaedt, 779
- Schulz, R, Guth, BD, Heusch, G. Pharmacological mechanisms to attenuate sympathetically induced myocardial ischemia, 43
- Seftel HC, *see* Berger, 219
- Seipel L, *see* Brilla, 211
- Sever P. Combination therapy with calcium-entry blockers and beta-adrenoceptor antagonists in hypertension, 327
- Shah S, Friedman HS. The relation of quinidine-induced elevation of serum digoxin concentration to the conversion of atrial fibrillation flutter, 929
- Shinebourne EA, *see* Redington, 21
- Silver PJ, Connell MJ, Dillon KM, Cumiskey WR, Volberg WA, Ezrin AM. Inhibition of calmodulin and protein kinase C by amiodarone and other Class III antiarrhythmic agents, 675
- Singh BN. Controlling cardiac arrhythmias: To delay conduction or to prolong refractoriness, 671
- Singh BN, *see* Feld, 191
- Singh BN, *see* Lessem, 355
- SK & F Ibopamine Working Group, 897
- Sleight P, *see* Coats, 303
- Smith TW, Pfeffer MA. The rationale for combined use of diuretics, digitalis, and vasodilators in congestive heart failure, 13
- Soares EG, *see* Bestetti, 171
- Sobolski J, *see* Ibrahim, 557
- Somers VK, *see* Coats, 303
- Sorensen, EV, Sterndorff B, Andersen MF, Faergeman O. Digoxin and xamoterol in patients with moderate chronic heart failure. A double-blind, randomized, controlled study, 203
- Spadoni R, *see* Binetti, 903
- Stark G, Stark U, Pilger E, Hönigl K, Bertuch H, Tritthart HA. The influences of elevated Mg^{2+} concentrations on cardiac electrophysiological parameters, 183
- Stark U, *see* Stark, 183
- Stein B, Fuster V. Role of platelet inhibitor therapy in myocardial infarction, 797
- Stern DM, *see* Nawroth, 117
- Sterndorff B, *see* Sorensen, 203
- Stokke O, *see* Sykulski, 427
- Storm T, *see* Sykulski, 427
- Strazzullo P, *see* Galletti, 135
- Sullivan, PA, Cervenká J, O'Connor DT, Dineen M. Fosenopril, an angiotensin-converting enzyme inhibitor, and propranolol: Comparative effects at rest and exercise on blood pressure, hormonal variables, and plasma potassium in essential hypertension, 57

- Sutton MR, *see* Dodd, 545
 Swynghedauw B. Transitory and permanent changes in gene expression in response to cardiac overload. Physiological and pharmacological relationships. A review, 947
 Sykulski R, Keller N, Storm T, Stokke O, Myhre T, Himanen P, Quitzau K. Double-blind comparison of tiapamil and atenolol in patients with mild to moderate hypertension: A multicenter trial, 427
 Taira N, *see* Gotanda, 507
 Taira N, *see* Imagawa, 81
 Taylor SH. Ibopamine and lifespan in heart failure, 1059
 Thormann J, Kramer W, Kremer P, Schlepper M. Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique), 145
 Thormann J, *see* Mitrovic, 771
 Tönnemann U, *see* Franz, 313
 Toselli T, *see* Longhini, 199
 Tritthart HA, *see* Stark, 183
 Unger P, Berkenboom G, Fontaine J. Study of ridazolol on isolated canine and human coronary arteries, 459
 Unger P, *see* Ibrahim, 557
 Valenzuela A, *see* Román, 767
 Vail HK, Anand IS. Cost of antihypertensive treatment. A point of view from India, 761
 Van de Fliedert E, *see* Bauer, 287
 Vandenburg, *see* Ritchie, 341
 Vanhoutte PM, Pearson, PJ. Reperfusion after acute coronary occlusion in dogs acutely and chronically impairs endothelium-dependent relaxation to aggregating platelets, 895
 Van Zwieten PA. Drugs interacting with alpha adrenoceptors, 121
 Van Zwieten PA, *see* Massingham, 731
 Varani E, *see* Binetti, 903
 Vivaldi MS, *see* Bernini, 829
 Volberg WA, *see* Silver, 675
 Volz M, *see* Mitrovic, 771
 Walker S, *see* Robinson, 25
 Waller DG, *see* Challenor, 275
 Watanabe K, *see* Hashimoto, 683
 Weishaar RE, Kobylarz-Singer, D, Klinkefus BA. New mechanisms for positive inotropic agents: Focus on the discovery and development of imazodan, 29
 Welsh NH, *see* Berger, 219
 Wilson JR, Mancini DM, Chance B. Skeletal muscle metabolism in congestive heart failure, 995
 Wong ECK, *see* Lee, 529
 Yokoyama H, *see* Gotanda, 507
 Zanchetti A. ACE inhibitors and cardioprotection, 855
 Zannoli R, *see* Galie, 91
 Zannoni M, *see* Arosio, 835
 Ziedler H, *see* Halabi, 441
 Zuccala G, *see* Carosella, 417

SUBJECT INDEX

- Acetabulol
 coronary artery disease treatment efficacy of, 287-293
 left ventricular hypertrophy in hypertension and, 313-316
 moderate hypertension treatment with, 364
 supraventricular arrhythmia treatment with, 367
 ACE inhibitors, *see* Angiotensin-converting enzyme (ACE) inhibitors
 N-acetylprocainamide
 quinidine plus digoxin comparison in atrial flutter with, 191-197
 Acute left heart failure, and SIN-1, 557-561
 Acute myocardial infarction (AMI)
 ACE inhibitors and, 885
 calcium antagonism and beta-blockade combination in, 356, 367, 478
 magnetic resonance imaging (MRI) of, 779-787
 neurohumoral activation in, 988, 990-991
 platelet inhibitor therapy in, 805-809
 Adenosine, and coronary vasodilation, 258-260
 Adenosine triphosphate (ATP)
 anipamil in cardioprotection and, 403-410
 coronary vasodilation and, 258-259
 Adrenergic receptors
 heart failure treatment and, 971-976
 hypertension treatment and, 413-415
 Aggregation coronary thrombosis, 799
 Ajmaline, and latent Chagas' cardiomyopathy, 171-175
 Alcohol, nonpharmacologic measures in hypertension, 849
 Aldosterone
 fosenopril and propranolol comparison and, 57-61
see also Renin-angiotensin-aldosterone system (RAAS)
 Alpha-adrenoceptors
 angina pectoris and, 260-262
 classification of, 121-124
 coronary artery vasoconstriction with, 258-259, 263
 drugs interacting with, 125-131
 ischemia and, 43-52
 lipids and lipoproteins in hypertension treatment and, 338
 ridazolol in canine coronary arteries and, 461
 signal transduction subsequent to stimulation of, 124-125
 Ambulatory blood pressure
 antihypertensive therapy monitoring with, 303-311
 costs of, 744
 Amiloride
 indapamide compared with hydrochlorothiazide and, 141-144
 mild congestive heart failure with, 897-901
 Amiodarone
 atrial flutter therapy with, 196
 calmodulin and protein kinase C inhibition by, 675-681
 digoxin interaction with, 25-27
 Amlodipine, 481
 canine ischemic myocardial studies with, 535-542
 hemodynamic properties of, 545-554
 pharmacokinetics of, 487-488
 Amrinone, and cardiovascular disease, 719
 AN-132, antiarrhythmic effects of, 683-688
 Anaerobic metabolism, and angina pectoris, 257
 Angina pectoris
 alpha-adrenoceptor activity and, 260-262
 beta-adrenoceptor antagonists and treatment of, 275-283
 beta-blockers and, 265-268
 calcium antagonism and, 263-265, 478
 calcium antagonism and beta-blockade combination in, 361-362
 nitrates in treatment of, 267
 neurohumoral changes and, 991-992
 pathological basis of, 249-254, 275-276
 pharmacology of acute effort, 257-268
 unstable, 252-254, 361-362, 478
see also Syndrome X
 Angiotensin, *see*
 Renin-angiotensin-aldosterone system (RAAS)
 Angiotensin-converting enzyme (ACE) inhibitors
 acute myocardial infarction and, 885
 alpha-adrenoceptor activity and, 131
 cardiac arrhythmias and, 873-881
 cardioprotection and, 855-856
 cardiovascular disease and pharmacokinetics of, 721-723
 congestive heart failure treatment with, 11-12, 382-383, 388-390, 883-888
 digoxin therapy with, 11-12
 dilated cardiomyopathy treatment and, 772, 774, 776, 777
 diuretics, digitalis, and vasodilator combination therapy and, 13-16
 diuretics used with, 11-12
 glycoside combined with, 15
 heart failure treatment with, 1013
 hemodynamics of, 865-872
 Indian experience with, 762
 left ventricular hypertrophy in hypertension and, 316
 lipids and lipoproteins in hypertension treatment and, 338
 low-dose enalapril in severe chronic heart failure and, 211-216
 mild congestive heart failure with, 897-901
 nifedipine in hypertension treatment combined with, 299
 nitrendipine in hypertension treatment combined with, 319-325
 renal function and, 886-887

- side effects of, 818
skeletal muscle blood flow and, 1018-1019
socioeconomic factors in selection of, 754
spontaneously hypertensive rat (SHR) with reduced cardiac mass and, 433-438
thiazide diuretics compared with, 815-818
- Angiotensin II**
alpha-adrenoceptor activity and, 131
hemodynamic response to, 866-872
- Anipamil**, 481
cardioprotection with, 403-411
- Anthopleurin-A (AP-A)**, 33
- Antiarrhythmic drugs**
N-acetylprocainamide and quinidine plus digoxin comparison in atrial flutter and, 191-197
calmodulin and protein kinase C inhibition by, 675-681
cardiovascular disease and pharmacokinetics of, 711-718
cardioprotective effects of, 151
CAST study of, 671-673, 708
sotalol and procainamide comparison in ventricular tachycardia and, 155-159
Wolff-Parkinson-White syndrome and, 73-78
see also specific drugs
- Anticoagulation therapy**, and myocardial infarction, 804, 805, 808-809
- Antihypertensive drugs**
alpha-adrenoceptor activity and, 127-129
ambulatory blood pressure monitoring in, 303-311
calcium-entry blockers combined with beta-adrenoceptor antagonists in, 327-332
cardiovascular disease and pharmacokinetics of, 720-721
costs of treatment with, 745-746
fosenopril and propranolol comparison in, 57-61
indapamide and hydrochlorothiazide plus amiloride comparison in, 141-144
Indian experience with, 761-764
lipids and lipoproteins and, 333-337, 767-769
long-term effects of, 521-522
new drug development costs and, 757-759
nonsteroidal antiinflammatory drugs (NSAID) and, 441-443
research costs and, 757-759
socioeconomic factors in selection of, 753-755
sodium intake and, 135-139
systolic and diastolic pressure in, 841-845
see also specific drugs
- Aorta**, and effects of SIN-1, 445-457
- APP** 201-533, 33
- Aprindine**, and cardiovascular disease, 718
- Arrhythmias**
encainide and flecainide (CAST study) of, 671-673
encainide effects on, 671-673, 697-702
ramipril effects on, 873-881
- Aspirin**
antithrombotic effect of, 800-801, 803-808
clinical trials of, 796
prevention of cardiovascular mortality with, 353-354, 805-806, 809-810
- Atenolol**, 357-358
ambulatory blood pressure monitoring of antihypertensive treatment with, 309-311
- hypertension treatment with, 343, 363-364, 365, 427-431
ischemia and, 50-52
lipids and lipoproteins in hypertension treatment and, 338
nifedipine in angina treatment compared with, 279, 281, 309-311, 360
tiapamil compared with, 427-431
- Atheroma**, and vasomotor tone, 250-251
- Atrial fibrillation**, 796, 929-930
- Atrial flutter**
N-acetylprocainamide and quinidine plus digoxin comparison in, 191-197
quinidine and, 929-930
- Atrial natriuretic peptide**, and heart failure, 983-984
- Atrioventricular (AV) node**, and magnesium concentrations, 183-188
- Automaticity**, and dihydropyridines and ethanol actions and interactions, 177-182
- Balloon occlusion**, and diprafenone, 146-152
- Bay K 8644**, and sinus node rhythm, 179-180, 181-182
- Bendroflumazide**, and mild hypertension treatment, 751-752
- Bepidil**, 481, 731-740
electrophysiological studies of, 732-733
intracellular actions with, 733-736
- Beta-adrenoceptors**
calcium-entry blockers in hypertension combined with, 327-332
ischemia and, 49, 50-52
ridazolol in canine coronary arteries and, 461, 462-463
vasodilators in hypertension combined with, 143-144
- Beta-adrenoceptor agonist**
cardiovascular disease and pharmacokinetics of, 719-720
moderate chronic heart failure therapy with, 203-209
see also specific agents
- Beta-adrenoceptor antagonists**
angina pectoris treatment with, 275-283
mechanism of action of, 276-277
side effects of, 282-283
- Beta-blockers**
acute myocardial infarction and, 367, 478
ambulatory blood pressure monitoring of antihypertensive treatment with, 309-311
angina pectoris and, 265-268, 358-359, 478
calcium antagonists combined with, 355-368, 478
exercise and hormonal responses to, 63-70
heart failure treatment with, 1013-1014
hypertension treatment and, 297-299, 338, 427-431
Indian experience with, 762
left ventricular hypertrophy in hypertension and, 313-316
lipids and lipoproteins and, 338, 767-769
nifedipine in hypertension treatment combined with, 297-299
pharmacological properties of, 356-358
silent ischemia and, 266
socioeconomic factors in selection of, 754
supraventricular arrhythmia treatment with, 366-367
- Beta receptors**, xamoterol effects on, 91-96
- B-HT 920**, and alpha-adrenoceptor activity, 130
- BK antagonist**, and cardiac arrhythmias, 875, 879
- Blood lipids**
antihypertensive therapy and, 335-338, 767-769
coronary artery disease and, 333
- Blood pressure**
antihypertensive therapy and monitoring of ambulatory, 303-311
calcium antagonists and, 135-139, 295-296
fosenopril and propranolol comparison for, 57-61
ibopamine and, 1045-1047
indapamide and hydrochlorothiazide plus amiloride comparison in, 142-143
naloxone and antihypertensive effect of captopril therapy in, 829-833
nonpharmacologic measures for lowering, 847-851
verapamil in elderly and, 421
- BM 14.578**, 33
- Bradykinin antagonist**, and cardiac arrhythmias, 873-881
- Bucindolol**, clinical trials of, 795
- Cadralazine**, and carotid circulation in hypertension, 859-863
- Calcium agonists and sinus node rhythm**, 177-182
- Calcium antagonists**
alpha-adrenoceptor activity and, 130-131, 263
ambulatory blood pressure monitoring of antihypertensive treatment with, 309-311
angina pectoris and, 263-268, 276-277, 478
beta blocking agents combined with, 355-368
binding sites for, 477
blood pressure regulation and, 295-296
cardioprotection with, 403-411
cardiovascular disease and pharmacokinetics of, 723-725
classification of, 477
congestive heart failure and vasodilation with, 380-381
diuretics combined with, 143-144
drug interactions with, 480, 494
hypertension treatment and, 338, 413-415, 427-431, 479
ischemia and, 51-53, 478
left ventricular hypertrophy in hypertension and, 313-316
long-term hemodynamic effects of, 519-521
mechanism of action of, 276-277, 477
pharmacological properties of, 356-358, 482-494
pre-existing disease and patient profiling with, 493-494
Raynaud's phenomenon therapy with, 397-400
second-generation agents in, 481
side effects of, 400, 480
sinus node rhythm and actions of, 177-182
sodium intake and blood pressure and, 135-139
supraventricular arrhythmia treatment with, 366-367, 479
- Calcium-channel blockers**
beta-adrenoceptor antagonists in hypertension and, 327-332
captopril in hypertension treatment combined with, 319-325
socioeconomic factors in selection of, 754
see also specific drugs

- Calcium homeostasis
 alpha-adrenoceptor activity and, 124-125
 bepridil and, 732-733
 cardiovascular function in heart failure and, 959-969
 excitation-contraction coupling and, 959
 inotropic agents and, 29-33, 34
 Calcium moderators, and sinus node rhythm, 177-182
 Calmodulin
 antiarrhythmic drugs and inhibition of, 675-681
 bepridil and effects of, 735-736
 Captopril
 cardiovascular disease and pharmacokinetics of, 721-722
 carotid circulation in hypertension and, 859-863
 digoxin combined with, 7-9, 15
 enoximone compared with, 1020-1021
 hemodynamic response to, 866-872
 ibopamine combined with, 1037
 lipids and lipoproteins in hypertension treatment and, 338
 mild-to-moderate congestive heart failure therapy with, 7-9
 naloxone and antihypertensive effects of, 829-833
 nitrendipine in hypertensive treatment combined with, 319-325
 severe chronic heart failure therapy with, 211, 215, 216
 spontaneously hypertensive rat (SHR) with reduced cardiac mass and, 433-438
 Cardiac actions
 dihydropyridines and ethanol actions and interactions and, 177-182
 SIN-1 and, 445-457
 verapamil in elderly and, 417-424
 xamoterol effects on, 91-96
see also Cardiovascular system
 Cardiac catheterization, and diprafenone, 146-152
 Cardiac overload, gene expression changes in, 947-955
 Cardiomyopathies
 ajmaline test to disclose latent, 171-175
 calcium antagonism and beta-blockade combination in, 367-368, 479
 congestive heart failure and, 987-988
 endothelium-derived relaxing factor (EDRF) and, 246
 Syndrome X and, 272-273
 vasopressor system in, 771-777
 Cardiovascular disease
 assessment of CNS symptoms in, 919-926
 gene expression changes in, 947-955
 pharmacokinetics of drugs affected by, 711-726
 primary prevention of, 809-810
 Cardiovascular system
 leukotrienes and, 499-503
 verapamil in elderly and, 417-424
see also Cardiac actions
 Cardioprotection
 ACE inhibitors and, 855-856
 anipamil and, 403-411
 metaprolol and, 529, 533
 ramipril and, 873-881
 Carotid circulation, and hypertension therapy, 859-863
 CAST study, 671-673
 Catecholamines of heart
 age-related increase in incidence of ventricular arrhythmias and, 163-168
 dilated cardiomyopathy treatment and, 771-777
 heart failure and, 980-981
 Central nervous system (CNS) symptoms, assessment of, 919-926
 Chagas' cardiomyopathy, and ajmaline test, 171-175
 Chest pain, and Syndrome X, 271-272
 Cholesterol
 hypercholesterolemia treatment with simvastatin and, 219-226
 pindolol and propranolol in hypertension treatment and, 767-769
 Cholestyramine
 hypercholesterolemia treatment with simvastatin and, 225-226
 Cinnarazine, 481
 Clofilium, and calmodulin and protein kinase C inhibition, 677-681
 Clonidine
 alpha-adrenoceptor activity and, 126-127
 ischemia and, 52
 Coagulation factors, and interaction with endothelium, 117-119
 Combination therapy, *see specific drugs*
 Compactin, 219
 Conductance (volume) catheter technique diprafenone with, 146-152
 Conduction velocities
 N-acetylprocainamide and quinidine in atrial flutter and, 196
 antiarrhythmic agents and, 671-673
 magnesium concentrations and cardiac electrophysiologic parameters in, 183-188
 Congenital heart disease, and digoxin therapy, 21-23
 Congestive heart failure (CHF)
 ACE inhibitors in, 11-12, 382-383, 388-390, 883-888
 calcium channel antagonists in, 479
 captopril and enoximone comparison in, 1020-1021
 captopril-digoxin combination in, 7-9, 15
 digitalis therapy in, 19-20, 473-476
 digoxin therapy in, 11-12
 direct-acting vasodilators and, 375-390
 diuretics, digitalis, and vasodilator combination therapy in, 13-16
 early, treatment in, 1007-1015
 felodipine therapy in, 903-910
 ibopamine and, 199-202, 897-901, 1025-1027, 1045, 1048, 1059-1062, 1065-1069
 ischemic cardiomyopathy and, 987-988
 left ventricular wall stress in, 385-386
 low-dose enalapril therapy in, 211-216
 muscle blood flow in, 1017-1020, 1022
 neuroendocrine responses in, 1008
 peripheral blood flow in, 1022-1023
 positron emission tomography (PET) in, 1001-1005
 types of heart failure in, 1010
 vasodilator therapy in, 375-381, 382-385, 386-390
 vasopressor system in, 771-777
 venodilator therapy in, 381-382
 volume expansion in, 941-944
 Coronary arteries
 ACE inhibitors and, 855-856
 endothelium-derived relaxing factor (EDRF) and, 241-246
 pathological basis of angina and, 249-254
 rizadolol in canine, 459-463
 Syndrome X and, 271-273
 Coronary artery disease (CAD)
 cholesterol and, 333-335
 lipoproteins and, 333
 magnetic resonance imaging (MRI) in, 779-787
 nifedipine and acebutolol in treatment of, 287-293
 positron emission tomography (PET) in, 1001-1005
 Coronary vasoconstriction
 alpha-adrenoceptor activity and, 124-125, 127, 258-259
 angina pectoris and, 257, 262, 265
 calcium antagonists and, 265
 dilated cardiomyopathy and, 771-777
 leukotrienes and, 501-503
 Coronary vasodilation
 nifedipine and, 295-296
 NKY-722 effects on, 81-89
 xamoterol effects on, 91-96
 Coronary vasomotor tone
 atheromatous arteries with, 250-251
 factors in regulation of normal, 249, 258-263
 sympathetic activation and, 43-53
 Cortisol, and beta-adrenergic blockade during exercise, 63-70
 Costs of hypertension treatment, 743-747, 931-933
 ACE inhibitors and thiazide diuretics comparison in, 815-816
 antihypertensive drugs based on systolic and diastolic pressure and, 841-845
 Australian experience with, 825-826
 Indian experience with, 762-763
 mild hypertension and, 749-752
 new drug development costs and, 757-759
 quality of life and, 821-823
 socioeconomic factors in drug selection and, 753-755
 world market for antihypertensive drugs and, 932-933
 Cromakalim, cardiohemodynamic effects of, 507-514
 Cyclosporine, and effects of cardiovascular disease, 726
 Desethylamiodarone
 calmodulin and protein kinase C inhibition by, 677-681
 digoxin-amiodarone interaction and, 25-27
 Dichlorobenzamil, 33
 Digitalis
 calcium homeostasis and, 31
 congestive heart failure treatment with, 19-20, 473-476
 diuretics and vasodilator combination therapy with, 13-16, 475
 Digoxin
 N-acetylprocainamide comparison in atrial flutter with quinidine plus, 191-197
 amiodarone interaction with, 25-27
 atrial fibrillation and, 929-930
 captopril combined with, 7-9, 15
 cardiovascular disease and pharmacokinetics of, 718-719
 congestive heart failure therapy with, 7, 474-475
 diuretic use and introduction of, 11-12
 heart failure treatment with, 1012-1013
 moderate chronic heart failure with, 203-209
 pediatric heart failure and, 21-23
 xamoterol combined with, 203-209
 Dihydropyridines
 angina pectoris treatment with, 281-282
 hypertension treatment with, 329, 330, 331
 mechanism of action of, 277
 sinus node rhythm and actions of, 177-182
 sodium intake in hypertension and, 135
 Dilated cardiomyopathy, and vasopressor system, 771-777
 Diltiazem, 477

- acute myocardial infarction and, 356
 angina pectoris treatment with, 264-265, 282, 360-361, 478
 cardiovascular disease and pharmacokinetics of, 724
 hypertension treatment with, 298, 329, 330, 331
 pharmacokinetics of, 486-487, 493
 supraventricular arrhythmia treatment with, 366-367
Diphenylalkylamines, 481
Diprafenone (DF)
 cardiodepressive effects of, 151-152
 end-systolic pressure-volume relationship and, 145-152
 Wolff-Parkinson-White syndrome therapy and, 73
Dipyridamole, antithrombotic effect of, 801, 803-808
Direct-acting vasodilators, in congestive heart failure, 375-390
Disopyramide, and effects of cardiovascular disease, 717-718
Diuretics
 ACE inhibitors compared with, 815-818
 cardiovascular disease and pharmacokinetics of, 720
 digoxin therapy with, 11-12, 475
 heart failure treatment in, 1012
 Indian experience with, 762
 left ventricular hypertrophy in hypertension and, 313, 316
 lipids and lipoproteins in hypertension treatment and, 337-338
 mild congestive heart failure with, 897-901
 nifedipine in hypertension treatment combined with, 299-300
 side effects of, 816-818
 socioeconomic factors in selection of, 754
see also specific diuretics
Dobutamine, combined with captopril, 15
Dopamine
 beta-adrenergic blockade during exercise and, 63-70
 captopril combined with, 15
 heart failure treatment with, 1014-1015
 isoprenaline and, 1043-1044
Dopaminergic agents
 inodilation and, 1049-1052
 receptors and, 1041-1043
Doxazosin, and alpha-adrenoceptor activity, 128-129
DPI-201-106, 33
Drug interactions
 calcium channel antagonists and, 480, 494
 encainide and, 702-703
 isoprenaline and, 1049
 sinus node rhythm and, 177-182
see also specific drugs
Elderly, verapamil effects in, 417-424
Electrocardiography (ECG)
 Chagas' cardiomyopathy with ajmaline test on, 171-175
 magnesium concentrations and cardiac electrophysiologic parameters in, 183-188
Electrophysiology, and sotalol and procainamide comparison in ventricular tachycardia, 155-159
Enalapril
 cardiovascular disease and pharmacokinetics of, 722-723
 congestive heart failure therapy with, 211-216, 389
 hemodynamic response to, 866-872
 left ventricular hypertrophy in hypertension and, 313
 lipids and lipoproteins in hypertension treatment and, 338
Encainide, 691-708
 cardiac arrhythmias and, 671-673, 697-702
 clinical trials of, 795
 pharmacokinetics of, 691-693
 side effects of, 703-704
Endothelium
 pathological basis of angina and, 249-254
 vitamin-K-dependent coagulation factors and interaction with, 117-119
 Endothelium-derived relaxing factor (EDRF), 241-246
 angina pectoris and, 249, 267
 atheromatous coronary arteries and, 251
 production of, 241-243
 prostacyclin and action of, 243-244
 End-systolic pressure-volume relationship (ESPVR), and diprafenone, 145-152
Enoximone
 captopril compared with, 1020-1021
 muscle blood flow and, 1022
 refractory heart failure and, 913-917
Epinephrine
 beta-adrenergic blockade during exercise and, 63-70
 Essential hypertension, *see* Hypertension
 Ethanol, and sinus node rhythm, 177-182
 Excitation-contraction coupling, and calcium, 959
Exercise
 beta-adrenergic blockade during continuous and intermittent, 63-70
 captopril-digoxin combination and, 16
 fosenopril and propranolol compared in, 57-61
 metoprolol dosage form and, 530
 nonpharmacologic measures in hypertension and, 849-850
Factor IX, and endothelium interactions in coagulation, 118, 119
Factor X, and endothelium interactions in coagulation, 118
Felodipine, 481
 cardiovascular disease and, 724-725
 chronic congestive heart failure therapy with, 903-910
 pharmacokinetics of, 488-489
Fendiline, 481
Fenoldopam, and congestive heart failure, 381
Flecainide
 cardiac arrhythmias and, 671-673, 708
 cardiovascular disease and, pharmacokinetics of, 717
 clinical trials of, 795
Flosquinan, and congestive heart failure, 380, 1019-1020
Flow, and endothelium-derived relaxing factor (EDRF), 242-243
Fosinopril, compared with propranolol, 57-61
Free fatty acids (FFA), and beta-adrenergic blockade during exercise, 63-70
Furosemide, and effects of cardiovascular disease, 720
Frusemide, and muscle blood flow, 1022
Gadolinium-DTPA, in magnetic resonance imaging (MRI) of acute myocardial infarction, 779-787
Gallopamil, 481
 left ventricular hypertrophy in hypertension and, 313, 316
 pharmacokinetics of, 489
 Gene expression, and cardiac overload, 947-955
 Glucose, and beta-adrenergic blockade during exercise, 63-70
 Glycoside, with vasodilator therapy, 15
 Growth hormone, and beta-adrenergic blockade during exercise, 63-70
 Growth signals, and cardiac overload, 953-954
Heart failure
 adrenergic receptor regulation in, 971-976
 digoxin and xamoterol therapy in moderate chronic, 203-290, 475
 enoximone and refractory, 913-917
 failure to respond to drug therapy in, 1055-1058
 neurohumoral changes in, 979-984
 SIN-1 and, 557-561
see also Congestive heart failure (CHF)
Hemodynamics
 angiotensin-converting enzyme (ACE) inhibitors and, 865-872
 amiloride in canine studies and, 545-554
 cromakalim and, 507-514
 felodipine and, 905-907
 isoprenaline and, 1029-1038, 1066
 long-term nicardipine and, 835-838
 pinacidil and, 507-514
 SIN-1 in acute left heart failure and, 557-561
 tiapamil and, 517-522
 His bundle, and magnesium concentrations, 183-188
HMG Co A reductase inhibitor, in hypercholesterolemia treatment, 219-226
Hydralazine
 cardiovascular disease and pharmacokinetics of, 721
 congestive heart failure and, 380, 386
Hydrochlorothiazide (HCTZ)
 indapamide compared with amiloride and, 141-144
 mild congestive heart failure with, 897-901
Hypercholesterolemia, and simvastatin treatment, 219-226
Hypertension
 acebutolol and nifedipine in treatment of, 313-316
 ACE inhibitors and thiazide diuretics comparison in, 815-818
 ambulatory blood pressure monitoring of treatment in, 303-311
 calcium antagonism and, 135-139, 479
 calcium antagonism and beta-blockade combination in, 363-367
 calcium-entry blockers combined with beta-adrenoceptor antagonists in, 327-332
 carotid circulation in, 859-863
 costs of treating, 743-747
 drugs interacting with alpha-adrenoceptors and treatment of, 127-129
 fosenopril and propranolol comparison in, 57-61
 indapamide and hydrochlorothiazide plus amiloride comparison in, 141-144
 Indian experience with, 761-764
 left ventricular hypertrophy in 313-316
 long-term nicardipine and hemodynamics in, 835-838
 mild, treatment of, 749-752, 763-764
 naloxone and antihypertensive effect of captopril therapy in, 829-833
 new drug development in, 757-759
 nicardipine therapy for, 36, 525-527
 nifedipine monotherapy for, 293-301, 341, 343

- nifedipine-prazosin interaction in, 413-415
 nitrendipine combined with captopril in treatment of, 319-325
 nonpharmacologic measures for lowering blood pressure in, 847-851
 oxaprozin-metoprolol interaction in, 441-443
 quality of life and treatment of, 821-823
 socioeconomic factors in selection of drugs for, 753-755
 spontaneously hypertensive rat (SHR) with reduced cardiac mass with, 433-438
 tiapamil therapy in, 427-431, 517-522
see also Spontaneously hypertensive rat (SHR)
- Hypertrophy of heart, and age-related increase in incidence of ventricular arrhythmias, 163-168**
- Ibopamine**
 combination therapy with, 1036-1037
 hemodynamics of, 1029-1038, 1066
 inodilation and, 1049-1052
 lifespan in heart failure and, 1059-1062
 mechanism of action of, 1029-1031
 mild congestive heart failure with, 897-901, 1025-1027, 1065-1069
 peripheral circulation in congestive heart failure and, 199-202
 pharmacologic profile of, 1044-1052
 receptor stimulation profile of, 1043-1044
 side effects of, 1048-1049
- Imazodan, 29**
 mechanisms of action of, 33-36
 pharmacologic studies of, 36-39
- Indapamide, compared with hydrochlorothiazide plus amiloride, 141-144**
- Indomethacin, and cardiac arrhythmias, 875, 879**
- Inotropic agents**
 cardiovascular disease and pharmacokinetics of, 718-719
 failure to respond to, 1055-1058
 moderate chronic heart failure therapy with, 203-209
 new mechanisms for, 29-39
see also specific agents
- Ischemia**
 alpha-adrenoceptors in, 43-52
 amlodipine in canine studies of, 535-542
 anipamil in cardioprotection and, 403-411
 bepridil and, 736-739
 beta-adrenoceptors in, 49, 50-52, 266-267
 calcium antagonism and beta-blockade combination in, 358-361
 metabolic basis of, 267-268
 norepinephrine release and, 991
 oxygen metabolism and, 893
 Syndrome X and, 272
- Ischemic cardiomyopathy**
 congestive heart failure and, 987-988
 neuroendocrine activation in 988-990
- Isradipine, 481**
 pharmacokinetics of, 489-490
 Raynaud's phenomenon and, 397-400
 side effects of, 400
- Ketanserin**
 alpha-adrenoceptor activity and, 129
 cardiovascular disease and pharmacokinetics of, 721
- Labetalol**
 alpha-adrenoceptor activity and, 129
 hypertension treatment and, 338, 365
- L-Dopa**
 age-related increase in incidence of ventricular arrhythmias and, 164, 167
- Left heart failure, and SIN-1, 557-561**
- Left ventricular function**
 low-dose enalapril in severe chronic heart failure and, 211-216
 digoxin and xamoterol therapy in moderate chronic heart failure and, 204-207
- Left ventricular hypertrophy**
 acebutolol and nifedipine in regression of, 313-316
 costs of treating, 743-747
 nicardipine therapy and, 525-527
 spontaneously hypertensive rat (SHR) with, 433-438
- Left ventricular wall stress, and congestive heart failure, 385-386**
- Leukotrienes, cardiovascular effects of, 499-503**
- Lidocaine, and effects of cardiovascular disease, 711-714**
- Lidoflazine, 481**
- Lipids**
 antihypertensive therapy and, 335-338, 767-769
 coronary artery disease and, 333
- Lipoproteins**
 antihypertensive therapy and, 336-337
 hypercholesterolemia treatment with simvastatin and, 219-226
- Lisinopril, and effects of cardiovascular disease, 723**
- Liver disease, and calcium antagonists, 484, 486, 487, 489, 490, 491, 492, 493-494**
- Lovastatin, 219, 224**
- Magnesium, and cardiac electrophysiologic parameters, 183-188**
- Magnetic resonance imaging (MRI), and acute myocardial infarction, 779-787**
- MCI-154, 33**
- Mental relaxation techniques, and hypertension, 850**
- Metoprolol**
 acute myocardial infarction and, 367
 controlled-release (CR) dosage form of, 529-533
 exercise and hormonal responses to, 63-70
 left ventricular hypertrophy in hypertension and, 316
 lipids and lipoproteins in hypertension treatment and, 338
 nifedipine in angina treatment compared with, 279, 281
 oxaprozin in hypertension and interaction with, 441-443
 pharmacokinetics of, 529-533
 silent ischemia with, 362-363
- Mevastatin, 219, 224**
- Mexiletine, and effects of cardiovascular disease, 716-717**
- Migraine, 479**
- Mild hypertension, treatment of, 749-752, 763-764**
- Milrinone**
 cardiovascular disease and pharmacokinetics of, 719
 clinical trials of, 795
 congestive heart failure and, 384-385
- Minor symptom evaluation questionnaire (MSE profile), 920**
- Minoxidil, in congestive heart failure treatment, 380**
- Mixed angina**
 beta-blockade in, 266
 calcium channel antagonists in, 478
- Molsidomine, and acute left heart failure, 557-561**
- Myocardial infarction**
 leukotrienes and, 502-503
 platelet inhibitor therapy in, 797-810
 secondary prevention of, 805-806
- Myocardium**
 magnesium concentrations and cardiac electrophysiologic parameters in, 183-188
 xamoterol effects on, 91-96
- Myosin heavy chain (MHC), and cardiac overload, 949-950**
- Naloxone, and antihypertensive effect of captopril therapy, 829-833**
- Nicainoprol, and cardiac arrhythmias, 879, 880-881**
- Nicardipine, 481**
 angina pectoris treatment with, 360
 hemodynamics and long-term use of, 835-838
 hypertension treatment with, 365, 525-527
 left ventricular hypertrophy regression with, 525-527
 pharmacokinetics of, 490-491
 silent ischemia with, 362-363
- Nifedipine, 357-358, 477**
 acute myocardial infarction (AMI) and, 356, 367
 ambulatory blood pressure monitoring of antihypertensive treatment with, 309-311
 antianginal effect of, 263-264, 358-359, 478
 blood pressure regulation and, 297-298
 cardiomyopathy treatment with, 367-368
 cardiovascular disease and pharmacokinetics of, 724
 chronic angina pectoris treatment with beta-adrenoceptor antagonists and, 275-283
 clinical trials of, 795-796
 coronary artery disease treatment efficacy of, 287-293
 diuretic effect of, 300-301
 hypertension treatment with, 293-301, 309-311, 313-316, 338, 341, 343, 363-365, 413-415, 479
 ischemia and, 50
 left ventricular hypertrophy in hypertension and, 313-316
 lipids and lipoproteins in hypertension treatment and, 338
 low-dose monotherapy in hypertension with, 341
 mechanism of action of, 277
 pharmacokinetics of, 484-486, 493
 prazosin combined with, 413-415
 propranolol compared with, 277-279
 side effects of, 282-283, 480
 supraventricular arrhythmia treatment with, 367, 479
- Nimodipine, 481**
 pharmacokinetics of, 491
 sinus node rhythm and, 178-179, 180-182
- Nisoldipine**
 angina pectoris treatment with, 262
 pharmacokinetics of, 491-492
- Nitrates**
 congestive heart failure and, 382
 hypertension therapy with, 843-845
 vascular endothelium in angina pectoris and, 267
- Nitrendipine, 481**
 amlodipine in canine studies compared with, 545-554
 blood pressure in hypertension and, 297

- captopril in hypertensive treatment combined with, 319-325
 cardiovascular disease and, 725
 combination therapy in hypertension with, 364-365
 pharmacokinetics of, 492-493
 sodium intake in hypertension and, 135-139
- Nitric oxide, and endothelium-derived relaxing factor (EDRF), 241, 267
- Nitroglycerin, and congestive heart failure, 381, 382
- Nitrovasodilators, and endothelium-derived relaxing factor (EDRF), 241
- NKY-722, 81-89
- Nonpharmacologic therapy for lowering blood pressure, 847-851
- Nonsteroidal antiinflammatory drugs (NSAID), and antihypertensive therapy, 441-443
- Noradrenaline (NA)
 alpha-adrenoceptor activity and, 123, 127, 128, 131
 myocardial reperfusion and, 894-895
 xamoterol effects on, 91-96
- Norepinephrine (NE)
 age-related increase in incidence of ventricular arrhythmias and, 164, 167
 beta-adrenergic blockade during exercise and, 63-70
 captopril-digoxin combination and, 16
 heart failure and, 971-972
 ischemia and release of, 991
 rizadolol in canine coronary arteries and, 461-462, 463
 sympathetically induced ischemia and, 44-45
- Obesity, nonpharmacologic measures in hypertension, 848-849
- Oxaprazin, and metoprolol in hypertension, 441-443
- Oxazepam, and assessment of CNS symptoms, 924-925
- Oxygen metabolism, and ischemia-reperfusion, 893
- Paracetamol, and effects of cardiovascular disease, 725-726
- PD 122,860, 33
- Pediatric heart failure, and digoxin, 21-23
- Peptoleukotrienes, 499-503
- Perindoprilat, hemodynamic response to, 866-872
- Peripheral circulation
 congestive heart failure and, 1022-1023
 ibopamine in congestive heart failure and, 199-202
 nifedipine in hypertension and, 293
- Phentolamine, and alpha-adrenoceptor activity, 127, 129
- Phosphodiesterase (PDE) inhibitors
 bepridil and effects of, 735-736
 calmodulin and, 676
 congestive heart failure and, 379-380
 mechanism of action of, 33-39
- Pimobendan, 33
- Pinacidil, cardiohemodynamic effects of, 507-514
- Pindolol, and lipids in hypertension, 767-769
- Platelet inhibitor therapy
 myocardial infarction and, 797-800, 802-810
 pharmacology of drugs in, 800-802
- Platelets
 adhesion to subendothelial sites of, 797
 aggregation of, 798
 endothelium-derived relaxing factor (EDRF) and, 242-243, 245-246
 reperfusion injury and, 895
- Positron emission tomography (PET), 1001-1005
 congestive heart failure on, 1002-1004
 coronary artery disease on, 1002
- Postsynaptic receptors
 alpha-adrenoceptor activity and, 121-124, 127
 ibopamine in congestive heart failure and, 202
- Potassium
 digoxin therapy and, 11-12
 fosenopril and propranolol comparison and, 57-61
- Potassium channel openers, 507
- Prazosin
 alpha-adrenoceptor activity and, 127-129
 cardiovascular disease and
 pharmacokinetics of, 720-721
 congestive heart failure and, 379
 left ventricular hypertrophy in hypertension and, 316
 nifedipine in hypertension treatment combined with, 413-415
- Premature ventricular contractions (PVCs), and encainide and flecainide therapy, 672
- Prenalator, and effects of cardiovascular disease, 719-720
- Presynaptic receptors, and alpha-adrenoceptor activity, 121-124
- Primary prevention, and, aspirin, 353-354
- Procainamide
 cardiovascular disease and
 pharmacokinetics of, 714-715
 sotalol in ventricular tachycardia compared with, 155-159
- Programmed electrical stimulation
 age-related increase in incidence of ventricular arrhythmias on, 163-168
 sotalol and procainamide comparison in ventricular tachycardia with, 155-159
- Prolactin, and beta-adrenergic blockade during exercise, 63-70
- Propranolol
 acute myocardial infarction and, 367
 amlodipine in canine studies compared with, 547, 550-552, 553-554
 angina pectoris treatment with, 358-360
 assessment of CNS symptoms and, 922-924
 cardiomyopathy treatment with, 367-368
 coronary vasoconstriction in angina with, 265-266
 fosenopril compared with, 57-61
 hypertension treatment and, 338, 365-366
 in hypertension and, 767-769
 nifedipine in angina treatment compared with, 277-279, 283, 364
 supraventricular arrhythmia treatment with, 366-367
- Prostacyclin
 cardiac arrhythmias and, 875, 879
 endothelium-derived relaxing factor (EDRF) and, 243-244
- Protein C, and endothelium interactions in coagulation, 117-118, 119
- Protein synthesis, and cardiac overload, 954-955
- Protein kinase C, and antiarrhythmic drugs, 675-681
- Quality of life, and health care delivery, 821-823
- Quinidine
 N-acetylprocainamide comparison in atrial flutter with, 191-197
 atrial fibrillation and, 929-930
 cardiovascular disease and
 pharmacokinetics of, 715-716
 ischemia and, 49
- Radionuclide ventriculography, in assessment of coronary artery disease treatment, 287-293
- Ramipril, and cardiac arrhythmias, 873-881
- Ramiprilat
 cardiac arrhythmias and, 875, 876, 878
 hemodynamic response to, 866-872
- Raynaud's phenomenon
 calcium channel antagonists in, 479
 isradipine therapy for, 397-400
- Refractoriness
 N-acetylprocainamide and quinidine in atrial flutter and, 196
 magnesium concentrations and cardiac electrophysiologic parameters in, 183-188
- Relaxation techniques, and hypertension, 850
- Renal function
 ACE inhibitors and, 886-887
 calcium antagonists and, 484, 486, 487
 489, 490, 491, 492, 493
 ibopamine and, 1043-1044, 1047
 leukotrienes and, 503
- Renin
 beta-adrenergic blockade during exercise and, 63-70
 nifedipine in hypertension treatment and, 298, 299
- Renin-angiotensin-aldosterone system (RAAS)
 congestive heart failure and, 383, 388, 389
 dilated cardiomyopathy treatment and, 772-777
 heart failure and, 981-983
- Reperfusion
 aggregating platelets in, 895
 amlodipine in canine studies of, 535-542
 anipamil in cardioprotection and, 403-411
 current concepts of injury in, 895
 ischemic brain and, 894
 mechanism of injury in, 894
 myocardial infarction and, 896
 noradrenaline release and, 894-895
 oxygen metabolism in, 893
 sarcolemmal changes in, 893-894
- Research costs for new drug development, 757-759
- Rizadolol, and coronary arteries, 459-463
- Risk factors
 lipids and lipoproteins in
 antihypertensive therapy and, 333-338
 mild hypertension treatment and, 749
- RNA synthesis, and cardiac overload, 954-955
- Salt in hypertension, nonpharmacologic measures for lowering, 848
- Shock, and leukotrienes, 503
- Silent ischemia
 bepridil in, 740
 beta-blockade in, 266, 362-363
 calcium channel antagonists in, 478
- Simvastatin, in hypercholesterolemia treatment, 219-226
- SIN-1
 acute left heart failure and, 557-561
 peripheral hemodynamics and
 viscoelastic properties of aorta and, 445-457
- Sinus node
 dihydropyridines and ethanol actions and interactions in, 177-182
 magnesium concentrations and cardiac electrophysiologic parameters in, 183-188
 quinidine therapy in atrial fibrillation and, 929-930

- Small vessels, and Syndrome X, 273
- Smooth muscle
 bepridil and, 733-734
 calcium antagonists and, 295-296
 endothelium-derived relaxing factor (EDRF) and, 241-246
- Socioeconomic factors in drug selection, 753-755
- Sodium homeostasis
 bepridil and, 733
 calcium antagonists in hypertension and, 135-139
 inotropic agents and, 32-33
 nifedipine in hypertension and, 300-301
- Sotalol
 atrial flutter therapy with, 196
 lipids and lipoproteins in hypertension treatment and, 338
 procainamide in ventricular tachycardia compared with, 155-159
 supraventricular arrhythmia treatment with, 366
- Spontaneously hypertensive rat (SHR)
 age-related increase in incidence of ventricular arrhythmias in, 163-168
 ventricular performance in, 433-438
- Statistical power of trial study, 306
- Strain-gauge plethysmography, and ibopamine in congestive heart failure, 199-202
- Stress test, in Syndrome X, 272
- Sulfinpyrazone, antithrombotic effect of, 810-802, 803-808
- Sulmazole, 33
- Sulpiride, and ibopamine in congestive heart failure, 199-202
- Supraventricular arrhythmias (SVA)
 antiarrhythmic agents and, 673
 calcium antagonism and beta-blockade combination in, 396-397, 479
 encainide and, 700-701, 706
- Syndrome X, 271-273
 diagnostic criteria for, 271-272
 endothelium-derived relaxing factor (EDRF) and, 246
- Systolic hypertension, therapy for, 841-845
- Terazosin, and alpha-adrenoceptor activity, 128-129
- Theophylline
 cardiovascular disease and pharmacokinetics of, 725
- Thiazide diuretics, *see* Diuretics
- Thrombomodulin, and endothelium interactions in coagulation, 117-118, 119
- Thrombosis
 endothelium and coagulation model for, 117-119
 platelet aggregation and thrombus formation in, 798-799
 unstable angina and, 252-254
- Thyroid hormone, and cardiac overload, 953
- Tiapamil, 481
 hypertension treatment with, 427-431, 517-522
 side effects of, 518-519
- Ticlopidine, antithrombotic effect of, 802, 803-808
- Timolol, and exercise responses, 63-70
- Tocainide, and effects of cardiovascular disease, 716
- Triglycerides
 hypercholesterolemia treatment with simvastatin and, 219-226
 pindolol and propranolol in hypertension treatment and, 768-769
- Trimazosin
 alpha-adrenoceptor activity and, 128-129
 congestive heart failure and, 379
- Trypanosomiasis, South American, 171-175
- Tumor necrosis factor (TNF), and coagulation, 118-119
- ULFS-49, and myocardial ischemia, 50-52
- Unstable angina, 252-254, 361-362, 478
- Urapidil
 alpha-adrenoceptor activity and, 129
 cardiovascular disease and pharmacokinetics of, 721
- Vascular effects of drugs, *see* Coronary vasodilation
- Vascular smooth muscle
 bepridil and, 733-734
 calcium antagonists and, 295-296
 endothelium-derived relaxing factor (EDRF) and, 241-246
- Vasoconstriction, *see* Coronary vasoconstriction
- Vasodilator drugs
 beta-adrenoceptor blockers combined with, 143-144
 cardiovascular function in heart failure and, 959-969
 congestive heart failure and, 883-888
 direct-acting, in congestive heart failure, 375-390
 diuretics and digitalis therapy combination therapy with, 13-16
 endothelium-derived relaxing factor (EDRF) and, 241-246
 failure to respond to, 1055-1058
 heart failure treatment with, 1013
 left ventricular hypertrophy in hypertension and, 316
 Raynaud's phenomenon treatment with, 397-400
 side effects of, 480
- Vasopressin, and heart failure, 983
- Vasospasm
 endothelium-derived relaxing factor (EDRF) and, 244-245
 transient reduction in coronary flow and, 251
- Vena cava balloon occlusion for rapid load changes, with diprafenone, 146-152
- Ventricular arrhythmias
 age-related increase in incidence of, 163-168
 AN-132 effects on, 683-688
 magnesium concentrations and cardiac electrophysiologic parameters in, 183, 186-188
- Ventricular fibrillation, and encainide, 700
- Ventricular tachycardia
 encainide and, 700
 sotalol and procainamide comparison for treatment of, 155-159
- Verapamil, 357, 477
 acute myocardial infarction and, 367
 angina pectoris treatment with, 264, 282, 358-360, 478
 cardioprotection with, 404, 406, 407, 410
 cardiovascular disease and pharmacokinetics of, 723-724
 cardiovascular effects in elderly of, 417-424
 hypertension treatment and, 296, 298, 329, 330, 365-366, 479
 pharmacokinetics of, 482-484, 493, 494
 side effects of, 480
 supraventricular arrhythmia treatment with, 367, 478
- Volume expansion, and congestive heart failure, 941-944
- Warfarin, clinical trials of, 796
- Wolff-Parkinson-White syndrome
 calcium channel antagonists in, 479
 diprafenone therapy for, 73-78
 encainide and, 701
- Xamoterol
 cardiovascular disease and pharmacokinetics of, 720
 clinical trials of, 796
 digoxin combined with, 203-209
 hemodynamic and coronary effects of, 91-96
 moderate chronic heart failure with, 203-209, 475
- Yohimbine, and alpha-adrenoceptor activity, 129-130

